Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Monsanto    MON

MONSANTO (MON)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Monsanto : Large U.S. farm study finds no cancer link to Monsanto weedkiller

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 04:42pm CEST
Farmer Edward Ford demonstrates granules of the weedkiller glyphosate on his arable farm in Brentwood

LONDON, (Reuters) - - A large long-term study on the use of the big-selling weedkiller glyphosate by agricultural workers in the United States has found no firm link between exposure to the pesticide and cancer, scientists said on Thursday.

Published in the Journal of the National Cancer Institute (JNCI), the study found there was no association between glyphosate, the main ingredient in Monsanto's popular herbicide RoundUp, "and any solid tumours or lymphoid malignancies overall, including non-Hogkin Lymphoma (NHL) and its subtypes".

It said there was "some evidence of increased risk of acute myeloid leukaemia (AML) among the highest exposed group", but added this association was "not statistically significant".

The findings are likely to impact legal proceedings in the United States against Monsanto, in which more than 180 plaintiffs are claiming exposure to RoundUp gave them cancer - allegations that Monsanto denies.

The findings may also influence a crucial decision due by the end of the year on whether glyphosate should be re-licensed for sale across the European Union.

EU countries had been due to vote on the issue on Thursday, but again failed to agree to a proposal for a five-year extension.

The EU decision has been delayed for more than a year after the World Health Organization's International Agency for Research on Cancer (IARC) reviewed glyphosate in 2015 and concluded it was "probably carcinogenic" to humans. Other bodies, such as the European Food Safety Authority, have concluded glyphosate is safe to use.

The research is part of a large and important project known as the Agricultural Health Study (AHS), which has been tracking the health of tens of thousands of agricultural workers, farmers and their families in Iowa and North Carolina.

Since the early 1990s, it has gathered and analysed detailed information on the health of participants and their families, and their use of pesticides, including glyphosate.

David Spiegelhalter, a professor of the Public Understanding of Risk at Britain's Cambridge University who has no link to the research, said Thursday's findings were from a "large and careful study" and showed "no significant relationship between glyphosate use and any cancer".

He added that the possible association with AML "is no more than one would expect by chance" and was not a concern.

Reuters reported in June how an influential scientist was aware of new AHS data while he was chairing a panel of experts reviewing evidence on glyphosate for the International Agency for Research on Cancer (IARC) in early 2015.

But since it had not at that time been published, he did not tell the expert panel about it and IARC's review did not take it into account.

The publication of the study on Thursday comes more than four years since drafts based on the AHS data on glyphosate and other pesticides were circulating in February and March 2013.

In a summary of the results, the researchers, led by Laura Beane Freeman, principal investigator of the AHS at the U.S. National Cancer Institute, said that among 54,251 (pesticide) applicators studied, 44,932, or 82.9 percent, used glyphosate.

"Glyphosate was not statistically significantly associated with cancer at any site," the summary said.

Scott Partridge, Monsanto's vice president of strategy, said the study results clearly showed the weedkiller was safe.

"This is the largest study of agricultural workers in history, over the longest period of time," he told Reuters. "It is the gold standard,... and it definitively demonstrates in a real-world environment that glyphosate doesn't cause cancer."

(Reporting by Kate Kelland, Editing by Gareth Jones)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MONSANTO
04/24Monsanto develops product to deactivate controversial farm chemical
RE
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20MONSANTO : Russian nod moves Bayer closer to wrapping up Monsanto deal
RE
04/20BAYER : Gains Russian Approval for Monsanto Deal
DJ
04/20RUSSIA GIVES GREEN LIGHT TO BAYER'S : Ifax
RE
04/19MONSANTO : Patent Issued for Plants and Seeds of Corn Variety CV360779 (USPTO 99..
AQ
04/19MONSANTO : Patent Issued for Plants and Seeds of Hybrid Corn Variety CH977140 (U..
AQ
04/19MONSANTO : Patent Issued for Plants and Seeds of Hybrid Corn Variety CH230932 (U..
AQ
04/19MONSANTO : Patent Issued for Plants and Seeds of Hybrid Corn Variety CH884093 (U..
AQ
04/19MONSANTO : New Dicamba Study Findings Have Been Reported by Investigators at Mon..
AQ
More news
News from SeekingAlpha
04/24Monsanto launches product to deactivate dicamba weedkiller 
04/21THE PASSIVE DGI CORE PORTFOLIO : Income, Safety, And Growth 
04/20Bayer wins Russian approval for Monsanto deal 
04/17Germany to go forward with plans to restrict Monsanto weedkiller 
04/17The U.S. Approves Bayer And Monsanto's Merger 
Financials ($)
Sales 2018 14 978 M
EBIT 2018 3 583 M
Net income 2018 2 484 M
Debt 2018 5 423 M
Yield 2018 1,72%
P/E ratio 2018 22,94
P/E ratio 2019 21,18
EV / Sales 2018 4,04x
EV / Sales 2019 3,80x
Capitalization 55 160 M
Chart MONSANTO
Duration : Period :
Monsanto Technical Analysis Chart | MON | US61166W1018 | 4-Traders
Technical analysis trends MONSANTO
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 126 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Hugh M. Grant Chairman & Chief Executive Officer
Brett D. Begemann President & Chief Operating Officer
Pierre C. Courduroux Chief Financial Officer & Senior Vice President
Robert T. Fraley Chief Technology Officer & Executive VP
Robert J. Stevens Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MONSANTO7.04%55 160
SOCIEDAD QUIMICA Y MINERA DE CHILE S.A.--.--%14 762
YARA INTERNATIONAL-13.99%11 460
UPL LTD-1.31%5 870
ISRAEL CHEMICALS LTD11.76%5 707
K+S11.78%5 477